| MAC (n = 701) | RIC (n = 722) | P value |
---|---|---|---|
Age (median, years) | 54 (50–72) | 57 (50–75) | <0.0001 |
Gender (male) | 381 (54Â %) | 395 (55Â %) | 0.89 |
F → M | 157 (23 %) | 193 (27 %) | 0.05 |
Cytogenetics | |||
 Good | 31 (8 %) | 43 (8 %) | 0.19 |
 Intermediate | 316 (77 %) | 393 (72 %) | |
 Poor | 66 (16 %) | 112 (20 %) | |
 Missing | 288 | 174 | |
Status at SCT | |||
 CR1 | 443 (63 %) | 450 (62 %) | 0.01 |
 CR2 | 84 (12 %) | 122 (17 %) | |
 Advanced | 174 (25 %) | 150 (21 %) | |
Stem cell source (PBSC) | 515 (73Â %) | 665 (92Â %) | <0.0001 |
In vivo T cell depletion | 81 (12Â %) | 239 (33Â %) | <0.0001 |
 ATG | 55 (8 %) | 172 (24 %) | |
 Alemtuzumab | 26 (4 %) | 67 (9 %) | |
Patient CMV + | 336 (66Â %) | 452 (73Â %) | 0.02 |
Donor CMV + | 284 (58Â %) | 398 (65Â %) | 0.009 |
Year of SCT (median, range) | 2002 (1997–2005) | 2003 (1997–2005) | <0.0001 |